AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00003533
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT04230681
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl
Trial: NCT01545453
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous dose every 4 weeks
Trial: NCT04233216
Drug: ISL
RxNorm normalized name: Dartisla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISL 0.75 mg capsule taken by mouth.
Trial: NCT04233216
Drug: Placebo to ISL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matched to ISL taken by mouth.
Trial: NCT04233216
Drug: Placebo to DOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matched to DOR taken by mouth.
Trial: NCT02617277
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1775 (adavosertib) is available in capsules for oral administration.
Trial: NCT02617277
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 (durvalumab) will be administered by IV infusion.
Trial: NCT03293927
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patient will receive IV fentanyl
Trial: NCT01768962
Drug: Once Daily Application of TFV RG 1% Gel - Vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal application
Trial: NCT01768962
Drug: Once Daily Application of TFV RG 1% gel - Rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal application
Trial: NCT00583869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient.
Trial: NCT00557427
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg - 40mg daily for 8 weeks
Trial: NCT02483624
Drug: BR-DIM
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
Trial: NCT02483624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02017639
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
Trial: NCT01909427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injections (SC) every 4 weeks through Week 12
Trial: NCT01909427
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
Trial: NCT00718965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet in the evening with dinner
Trial: NCT01078623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control twice daily
Trial: NCT01690637
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01431326
Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01358760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal suppository
Trial: NCT01298973
Drug: Viscoat
RxNorm normalized name: Viscoat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One group will receive Viscoat for incision closure
Trial: NCT01257802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
Trial: NCT02808871
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times daily for 52 weeks
Trial: NCT03161132
Drug: Pegylated Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 40mg/m2 every 28 days intravenous
Trial: NCT03613662
Drug: SP-102
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT02794077
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
Trial: NCT00115791
Drug: RSD1235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00115791
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00932737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-5 tablets per episode
Trial: NCT00932737
Drug: HBB 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug, one to five tablets per episode
Trial: NCT04110587
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
Trial: NCT04110587
Drug: corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone, 4 mg I.V. (Intraoperative)
Trial: NCT04110587
Drug: Antiinflammatories
RxNorm normalized name: ANTIINFLAMMATORY AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
Trial: NCT04110587
Drug: Analgesics
RxNorm normalized name: ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metamizol 575 mg / 8h by mouth (Post-operatively)
Trial: NCT02176187
Drug: Berodual® Respimat® inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenoterol hydrobromide 50μg + ipratropium bromide 20μg
Trial: NCT02176187
Drug: Berodual® metered dose inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fenoterol hydrobromide 50μg + ipratropium bromide 20μg
Trial: NCT03475693
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg tablets given once in the ED, and prescribed to take BID for 5 days total after discharge.
Trial: NCT03475693
Drug: Zofran ODT 4 MG Disintegrating Oral Tablet
RxNorm normalized name: Zofran ODT 4 MG Disintegrating Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given once in the Emergency department
Trial: NCT03451942
Drug: FLOT regimen chemotherapy
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOT regimen chemotherapy
Trial: NCT00990938
Drug: IMO-2125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
Trial: NCT04349371
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take two tabs of placebo for every day for one week and then two tabs of placebo for 1 day a week thereafter for study duration of 3 months).
Trial: NCT00971763
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00971763
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02655354
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-depressant
Trial: NCT01703741
Drug: Testosterone Gel (FE 999093)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03350620
Drug: NVK-002 Concentration 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication will be administered, once daily (QD)
Trial: NCT03350620
Drug: NVK-002 Concentration 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication will be administered, once daily (QD)
Trial: NCT03350620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) will be administered, once daily (QD)
Trial: NCT01515007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06091579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo inhalation using a Plastiape capsule-based dry powder inhaler.
Trial: NCT04330183
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3cc of normal saline
Trial: NCT02324985
Drug: S-Ibuprofen Topical Gel 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Ibuprofen Topical Gel 5% applied every 6 hours
Trial: NCT00562627
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraoperative and 1. postoperative day
Trial: NCT00562627
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: continuous postoperatively
Trial: NCT00597701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01107418
Drug: RO5185426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage b) orally twice daily, days 1-15 (morning dose)
Trial: NCT01107418
Drug: RO5185426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage c) orally twice daily, days 1-15 (morning dose)
Trial: NCT01107418
Drug: RO5185426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage d) orally twice daily, days 1-15 (morning dose)
Trial: NCT01107418
Drug: RO5185426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960 mg orally twice daily, from day 22 onward
Trial: NCT01107418
Drug: RO5185426
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage a) orally twice daily, days 1-15 (morning dose)
Trial: NCT00017238
Drug: KRN5500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01155219
Drug: Geltim LP 1 mg/g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop in the conjunctival sac of each eye in the morning (84 days).
Trial: NCT00460369
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets 20/120 mg~* 1 tablet twice daily for 3 days below 15 kg of bodyweight~* 2 tablets twice daily for 3 days below 24 kg of bodyweight~* 3 tablets twice daily for 3 days below 35 kg of bodyweight
Trial: NCT02886689
Drug: TNF-alpha antagonist and other biotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00421785
Drug: Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00185991
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours).
Trial: NCT02889692
Drug: YiQiFang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Trial: NCT02889692
Drug: YangYinFang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Trial: NCT02889692
Drug: YiQiYangYinFang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
Trial: NCT02889692
Drug: placebo granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
Trial: NCT02367131
Drug: JARDIANCE®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JARDIANCE®
Trial: NCT02231164
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo
Trial: NCT00144131
Drug: Aranesp®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03504397
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received an IV infusion (as a minimum of 2-hour infusion) of placebo matched to zolbetuximab on C1D1 followed by subsequent doses every 3 weeks starting from C1D22 until participant met study treatment discontinuation criteria. Each cycle was approximately 42 days.
Trial: NCT03504397
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received up to 12 treatments of 5-fluorouracil over 4 or more cycles administered by IV bolus 400 mg/m\^2 over 5 to 15 minutes followed by 2400mg/m\^2 over 46-48 hours continuous IV infusion every 2 weeks for 4 cycles. Participants could continue to receive 5-fluorouracil on Days 1, 15 and 29 of each cycle at the investigator's discretion or until the participant met the study treatment discontinuation criteria. Each cycle was approximately 42 days.
Trial: NCT03566511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
Trial: NCT02741271
Drug: MF/F MDI 100/10 mcg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID.
Trial: NCT02723994
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02723994
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02723994
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02723994
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02723994
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00373685
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: open-label
Trial: NCT02570165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
Trial: NCT00668031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
Trial: NCT04060862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 3: Matching placebo, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
Trial: NCT03307512
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
Trial: NCT04735536
Drug: CT1812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Treatment- CT1812 at a dose of 300mg
Trial: NCT00111878
Drug: MEDI-534
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04343729
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injectable saline solution
Trial: NCT00689598
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg po qd 25 mg po bid
Trial: NCT00689598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg po qd
Trial: NCT03300960
Drug: Provera 10 mg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
Trial: NCT00455767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00700570
Drug: capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
Trial: NCT01454115
Drug: Placebo matching BMS-708163
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 0 mg, Once daily, once
Trial: NCT01454115
Drug: Placebo matching BMS-708163
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, Oral, 0 mg, Once daily, once
Trial: NCT02180269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of placebo matched to JNJ-54861911 on Day 1.
Trial: NCT02097043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00530101
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:~Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2
Trial: NCT00736879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Once Daily, Up to 24 weeks
Trial: NCT02088242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
Trial: NCT02004392
Drug: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02797015
Drug: RPC1063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule daily
Trial: NCT00415350
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin Tablet 250 mg daily
Trial: NCT02608320
Drug: New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.